The document discusses potential strategies for defeating bacteria and viruses. It considers developing drugs targeting pathogens' metabolic networks and virulence systems, which could have advantages over traditional antibiotics in being harder for pathogens to develop resistance against. For bacteria, it outlines developing small molecule drugs targeting metabolic pathways could be achieved through computational modeling and screening. For viruses, it proposes engineering live or recombinant vaccines and developing small molecules targeting processes like cell entry or viral assembly, though each strategy would require optimization over several years. The target customers mentioned are NATO and small-to-medium pharmaceutical companies.